Cargando…
S100-EPISPOT: A New Tool to Detect Viable Circulating Melanoma Cells
Metastatic melanoma is one of the most aggressive and drug-resistant cancers with very poor overall survival. Circulating melanoma cells (CMCs) were first described in 1991. However, there is no general consensus on the clinical utility of CMC detection, largely due to conflicting results linked to...
Autores principales: | Cayrefourcq, Laure, De Roeck, Aurélie, Garcia, Caroline, Stoebner, Pierre-Emmanuel, Fichel, Fanny, Garima, Françoise, Perriard, Françoise, Daures, Jean-Pierre, Meunier, Laurent, Alix-Panabières, Catherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678250/ https://www.ncbi.nlm.nih.gov/pubmed/31330795 http://dx.doi.org/10.3390/cells8070755 |
Ejemplares similares
-
Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study
por: Mazard, Thibault, et al.
Publicado: (2021) -
Circulating Tumor Cell Detection and Polyomavirus Status in Merkel Cell Carcinoma
por: Boyer, Magali, et al.
Publicado: (2020) -
Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma
por: Boyer, Magali, et al.
Publicado: (2020) -
Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones
por: Cayrefourcq, Laure, et al.
Publicado: (2021) -
Epithelial-to-Mesenchymal Plasticity in Circulating Tumor Cell Lines Sequentially Derived from a Patient with Colorectal Cancer
por: Balcik-Ercin, Pelin, et al.
Publicado: (2021)